Pelvalon Names Jonathan R. Ward as Vice President of Sales

Experienced Senior Sales Executive Joins Company from Boston

SUNNYVALE, Calif.–(BUSINESS WIRE)–Pelvalon, a medical device company dedicated to developing innovative
solutions for women suffering from loss of bowel control, today
announced the appointment of Jonathan R. Ward as Vice President of
Sales. Mr. Ward will report directly to Pelvalon’s CEO, Miles Rosen.

Mr. Ward joins Pelvalon with more than 20 years of sales experience in
the medical device industry, including specific category experience with
incontinence and female pelvic health products. Most recently, he served
as Southeast Area Sales Director, Urology and Pelvic Health, for Boston
Scientific Corporation. Prior to Boston Scientific, Mr. Ward spent more
than a decade in national and regional sales leadership positions at
American Medical Systems. Earlier in his career, he served as a top
sales representative for Depuy.

“I am thrilled to add a Vice President of Sales with the leadership,
sales and category expertise of Jon Ward,” said Miles Rosen, co-founder
and CEO of Pelvalon. “As we prepare to expand the launch of the
first-of-its-kind Eclipse System, Jon’s experience in accelerating
adoption of new technologies will be extremely valuable. Our strong
emphasis on clinical research and development, paired with Jon’s
industry relationships and experience in commercialization strategies,
will help us meet our goal of helping women with loss of bowel control.”

More than 20 million women in the U.S. suffer from loss of bowel
control, sometimes called accidental bowel leakage (ABL) or fecal
incontinence (FI). This debilitating condition can be caused by
pregnancy, childbirth, nerve or muscle damage in the pelvic region, and
gastrointestinal disorders such as irritable bowel syndrome (IBS).
Sometimes women will feel a strong urge to have a bowel movement; other
times, leakage can occur without warning. Typical first-line treatments
include dietary changes, exercise and medications. If the issue
persists, patients may need to move on to more invasive and costly
treatments, such as surgery, surgical implants, or injections. The
Eclipse System provides a new, non-surgical option for these women.

The Eclipse System has recently been made available via a limited
commercial rollout in select centers of excellence in Illinois,
Michigan, Alabama, California, and North Carolina.

“I have been very encouraged to hear the patient and physician response
to the Eclipse System in Pelvalon’s early commercial efforts,” said
Ward. “I am thrilled to be able to build on the efforts of the company
and current clinical evidence to continue the limited release and, in
time, expand access so more patients can return to living their lives to
the fullest.”

About the Eclipse System

The Eclipse System is the first vaginal insert designed to provide
immediate bowel control. Placed in the same location as a tampon or a
diaphragm, the insert contains no hormones or drugs and can be removed
at any time. In a clinical trial, among the women who were successfully
fit and used the insert for one month, Eclipse was effective in 86% of
those women. The most common adverse event was pelvic discomfort, most
frequently associated with the fitting process and typically resolved by
just removing the insert. At the end of the study, 96% of participants
successfully fit with the insert found the Eclipse to be comfortable,
and 98% reported that they would recommend it to a friend.1

About Pelvalon

Headquartered in Sunnyvale, California, privately held Pelvalon aims to
improve the lives of women who suffer from bowel control
problems. Founded in 2010, Pelvalon’s groundbreaking technology
originated from Stanford University’s Biodesign program, a collaboration
between the schools of medicine and engineering. For more information,

1Richter, HE, Matthews, CA, Muir T, et al. A Vaginal
Bowel-Control System for the Treatment of Fecal Incontinence. Obstetrics
& Gynecology. 2015; 125(3):540-547.


Nicole Osmer, 650.454.0505